CN111741766A - 用于诱导针对乙型肝炎病毒(hbv)的免疫应答的方法和组合物 - Google Patents

用于诱导针对乙型肝炎病毒(hbv)的免疫应答的方法和组合物 Download PDF

Info

Publication number
CN111741766A
CN111741766A CN201880089584.0A CN201880089584A CN111741766A CN 111741766 A CN111741766 A CN 111741766A CN 201880089584 A CN201880089584 A CN 201880089584A CN 111741766 A CN111741766 A CN 111741766A
Authority
CN
China
Prior art keywords
hbv
seq
antigen
sequence
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880089584.0A
Other languages
English (en)
Chinese (zh)
Inventor
D·博登
H·霍顿
J-M·E·F·M·尼芙斯
S·罗伊
J·H·H·V·屈斯泰
R·C·察恩
M·卡拉
D·德普特尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bavarian Nordic AS
Janssen Sciences Ireland ULC
Original Assignee
Bavarian Nordic AS
Janssen Sciences Ireland ULC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic AS, Janssen Sciences Ireland ULC filed Critical Bavarian Nordic AS
Publication of CN111741766A publication Critical patent/CN111741766A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10131—Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN201880089584.0A 2017-12-19 2018-12-18 用于诱导针对乙型肝炎病毒(hbv)的免疫应答的方法和组合物 Pending CN111741766A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762607439P 2017-12-19 2017-12-19
IB2017058148 2017-12-19
IBPCT/IB2017/058148 2017-12-19
US62/607,439 2017-12-19
PCT/IB2018/060257 WO2019123250A1 (en) 2017-12-19 2018-12-18 Methods and compositions for inducing an immune response against hepatitis b virus (hbv)

Publications (1)

Publication Number Publication Date
CN111741766A true CN111741766A (zh) 2020-10-02

Family

ID=65201641

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880089584.0A Pending CN111741766A (zh) 2017-12-19 2018-12-18 用于诱导针对乙型肝炎病毒(hbv)的免疫应答的方法和组合物

Country Status (12)

Country Link
EP (1) EP3727446A1 (ja)
JP (1) JP2021506300A (ja)
KR (1) KR20200100745A (ja)
CN (1) CN111741766A (ja)
AU (1) AU2018389786A1 (ja)
BR (1) BR112020012273A2 (ja)
CA (1) CA3086325A1 (ja)
IL (1) IL275423A (ja)
MA (1) MA51312A (ja)
MX (1) MX2020006471A (ja)
SG (1) SG11202005710YA (ja)
WO (1) WO2019123250A1 (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202091516A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv)
EA202091517A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и устройство для доставки вакцин против вируса гепатита b (hbv)
EA202091513A1 (ru) 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани Вакцины против вируса гепатита b (hbv) и их применение
WO2020255055A1 (en) * 2019-06-20 2020-12-24 Janssen Sciences Ireland Unlimited Company Self-replicating rna molecules for hepatitis b virus (hbv) vaccines and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101248173A (zh) * 2005-04-08 2008-08-20 墨尔本保健公司 对于抗病毒核苷试剂具有抗性的乙型肝炎病毒变异体及其应用
WO2017121791A1 (en) * 2016-01-12 2017-07-20 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Means and methods for treating hbv

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA92121A (en) 1904-11-07 1905-03-14 William Waid Paddock Pressure filter
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
US6041252A (en) 1995-06-07 2000-03-21 Ichor Medical Systems Inc. Drug delivery system and method
US6083716A (en) 1996-09-06 2000-07-04 The Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
CA2285056C (en) 1997-04-03 2004-12-14 Iacob Mathiesen Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
US5873849A (en) 1997-04-24 1999-02-23 Ichor Medical Systems, Inc. Electrodes and electrode arrays for generating electroporation inducing electrical fields
GB0023203D0 (en) 2000-09-21 2000-11-01 Isis Innovation Vaccination method
US6117660A (en) 1997-06-10 2000-09-12 Cytopulse Sciences, Inc. Method and apparatus for treating materials with electrical fields having varying orientations
IL133710A0 (en) 1997-06-30 2001-04-30 Rhone Poulence Rorer S A Improved method for transferring nucleic acid into the striped muscle and combination thereof
WO2000002621A1 (en) 1998-07-13 2000-01-20 Genetronics, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US6319901B1 (en) 1998-10-15 2001-11-20 Ichor Medical Systems, Inc. Methods for prolonging cell membrane permeability
AU777041B2 (en) 1999-05-17 2004-09-30 Crucell Holland B.V. Adenovirus derived gene delivery vehicles comprising at least one element of adenovirus type 35
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
NZ524661A (en) 2000-11-23 2005-03-24 Bavarian Nordic As Modified vaccinia ankara virus variant
AU2002356690B2 (en) 2001-12-04 2008-07-24 Bavarian Nordic A/S Flavivirus NS1 subunit vaccine
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US6912417B1 (en) 2002-04-05 2005-06-28 Ichor Medical Systmes, Inc. Method and apparatus for delivery of therapeutic agents
PL208588B1 (pl) 2002-04-25 2011-05-31 Crucell Holland Bv Rekombinowane adenowirusy, wyizolowane kwasy nukleinowe, komórki pakujące oraz sposoby zwiększania stabilności i/lub pojemności upakowania rekombinowanego adenowirusa
JP4495587B2 (ja) 2002-04-25 2010-07-07 クルセル ホランド ベー ヴェー 組換えアデノウイルスベクターおよびその使用
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
CN107723298A (zh) 2004-01-23 2018-02-23 Msd意大利有限公司 黑猩猩腺病毒疫苗载运体
CN102886101B (zh) 2004-03-08 2015-10-28 艾科医疗系统公司 改进的治疗剂电介导输送设备
US20100143302A1 (en) 2006-03-16 2010-06-10 Crucell Holland B.V. Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
WO2008048632A1 (en) 2006-10-17 2008-04-24 Vgx Pharmaceuticals, Inc. Electroporation devices and methods of using same for electroporation of cells in mammals
WO2009056535A2 (en) * 2007-10-29 2009-05-07 Genimmune N.V. Methods and kits for inducing a ctl response using a prime boost regimen
AU2009319336B2 (en) 2008-11-27 2015-03-26 Bavarian Nordic A/S Promoters for recombinant viral expression
KR101763093B1 (ko) 2009-02-02 2017-07-28 글락소스미스클라인 바이오로지칼즈 에스.에이. 시미안 아데노바이러스 핵산- 및 아미노산-서열, 이를 포함하는 벡터 및 이의 용도
WO2010085984A1 (en) 2009-02-02 2010-08-05 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
US8394385B2 (en) 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
WO2011015656A2 (en) * 2009-08-07 2011-02-10 Transgene Sa Composition for treating hbv infection
WO2012082918A1 (en) 2010-12-14 2012-06-21 The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Adenovirus serotype 26 and serotype 35 filovirus vaccines
US10111946B2 (en) 2012-06-22 2018-10-30 Bavarian Nordic A/S Poxviral vectors for low antibody response after a first priming immunization
KR20200087880A (ko) 2012-10-28 2020-07-21 버베리안 노딕 에이/에스 강력한 ｔ-세포 및 항체 반응을 위한 ｐｒ13.5 프로모터
WO2017021776A1 (en) 2015-07-31 2017-02-09 Bavarian Nordic A/S Promoters for enhancing expression in poxviruses
MX2018011742A (es) 2016-03-28 2019-02-14 Ichor Medical Systems Inc Metodo y aparato para suministro de agentes terapeuticos.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101248173A (zh) * 2005-04-08 2008-08-20 墨尔本保健公司 对于抗病毒核苷试剂具有抗性的乙型肝炎病毒变异体及其应用
WO2017121791A1 (en) * 2016-01-12 2017-07-20 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Means and methods for treating hbv

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ARTURO REYES-SANDOVAL ET AL.: ""Prime-Boost Immunization with Adenoviral and Modified Vaccinia Virus Ankara Vectors Enhances the Ourability and Polyfunctionality of Protective Malaria C08(+) T-Cell Responses"", 《INFECTION AND IMMUNITY》, vol. 78, no. 1, pages 145 - 153, XP002778539 *
PERRINE MARTIN ET AL.: ""TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice"", 《 HEPATOLOGY》, vol. 64, no. 12, pages 1961 - 1971, XP055565264, DOI: 10.1136/gutjnl-2014-308041 *
RALF BARTENSCHLAGER ET AL: ""Expression of the P-protein of the human hepatitis B virus in a vaccinia virus system and detection of the nucleocapsid-associated P-gene product by radiolabelling at newly introduced phosphorylation sites",", 《NUCLEIC ACIOS RESEARCH》, vol. 20, no. 2, pages 195 - 202, XP055454054, DOI: 10.1093/nar/20.2.195 *

Also Published As

Publication number Publication date
WO2019123250A1 (en) 2019-06-27
EP3727446A1 (en) 2020-10-28
KR20200100745A (ko) 2020-08-26
MA51312A (fr) 2020-10-28
MX2020006471A (es) 2020-09-22
JP2021506300A (ja) 2021-02-22
CA3086325A1 (en) 2019-06-27
SG11202005710YA (en) 2020-07-29
BR112020012273A2 (pt) 2020-11-24
IL275423A (en) 2020-08-31
AU2018389786A1 (en) 2020-06-18

Similar Documents

Publication Publication Date Title
CN110951756B (zh) 表达SARS-CoV-2病毒抗原肽的核酸序列及其应用
US11759516B2 (en) Nucleic acid vaccine against the SARS-CoV-2 coronavirus
KR20200101416A (ko) B형 간염 바이러스(hbv) 백신 및 그 용도
CN108779472B (zh) 针对乙型肝炎病毒的疫苗
US11020476B2 (en) Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV)
US11725194B2 (en) Hepatitis B virus (HBV) vaccines and uses thereof
CN111741766A (zh) 用于诱导针对乙型肝炎病毒(hbv)的免疫应答的方法和组合物
KR20180100228A (ko) Hbv를 치료하기 위한 수단 및 방법
CN115058452A (zh) Cmv疫苗
TW201734208A (zh) Ｈｂｖ聚合酶突變體
CN114340664A (zh) 乙型肝炎病毒(HBV)疫苗和靶向HBV的RNAi的组合
TWI828168B (zh) 用作b型肝炎病毒(hbv)疫苗之自我複製rna分子及其用途
CA3173795A1 (en) Attenuated poxvirus vector based vaccine for protection against covid-19
KR20220038755A (ko) 한타바이러스 항원성 조성물
KR20220041080A (ko) B형 간염 바이러스(hbv) 백신 및 항-pd-1 또는 항-pc-l1 항체의 조합
Brillowska et al. Protection of cattle against bovine leukemia virus (BLV) infection could be attained by DNA vaccination.
WO2020255010A1 (en) Combination of recombinant interleukin 12 construct and hepatitis b virus (hbv) vaccines
KR20220041079A (ko) B형 간염 바이러스(hbv) 백신 및 항-pd-1 항체의 조합
TW201928061A (zh) 誘發抗b型肝炎病毒(hbv)免疫反應之方法及組合物
US20220324916A1 (en) Hepatitis B Virus (HBV) Vaccines and Uses Thereof
GB2624391A (en) Recombinant LSDV vectored bovine coronavirus antigen constructs
TW201930594A (zh) B型肝炎病毒(hbv)疫苗及其用途
EA045279B1 (ru) Вакцины против вируса гепатита b (hbv) и их применение

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination